Study to assess the safety and effectiveness of remdesivir in people with severe COVID-19

ISRCTN ISRCTN15874265
DOI https://doi.org/10.1186/ISRCTN15874265
EudraCT/CTIS number 2020-000841-15
IRAS number 282007
ClinicalTrials.gov number NCT04292899
Secondary identifying numbers GS-US-540-5773, IRAS 282007, CPMS 45460
Submission date
29/10/2020
Registration date
03/11/2020
Last edited
19/03/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
The purpose of this study is to test a new medicine, remdesivir (RDV) for people with COVID-19.
There are no approved medications to treat COVID-19, a new disease caused by a virus called SARS-CoV-2 that was just identified in late 2019. COVID-19 can cause many symptoms. The symptoms can range from mild to very severe and sometimes can lead to death. The purpose of this study is to see if RDV can improve the health of people with severe COVID-19.

Who can participate?
Persons 12 years of age or older who have SARS-CoV-2 infection less than 4 days before joining the study, and are in hospital

What does the study involve?
Part A of this study included approximately 400 participants with severe COVID-19 infection. Part B of this study included approximately 5,600 participants also with severe COVID-19 infection. The treatment assignment for participants in Part B was based on whether or not they were on mechanical ventilation. The study doctor conducted a screening visit to make sure they could join the study.
Part A
Randomized study: The researchers used a computer program to randomly choose the treatment each participant took. This helped make sure the treatments were chosen fairly. Participants had an equal chance of receiving RDV for 5 days or RDV for 10 days. In both treatment arms, participants still received standard of care treatment.
Open label study: Each participant knew which treatment length they would get and the doctors and study staff also knew.

Part B was also open-label.
Participants who qualified for the study and decided to join received RDV by injections directly into the vein

Participants were followed up for 10 days.

What are the possible benefits and risks of participating?
Possible benefits: Participants may not get any benefit from taking part in this study. Studies are a way for doctors to see if a drug is useful in treating a disease. Taking part in this study may help us know more about how to treat people with COVID-19 in the future.
Possible risks: All medicines could potentially cause side effects in some people. Increases in levels of liver enzymes have been seen in some people who have taken RDV, which may be a sign of inflammation or damage to the cells in the liver.

Where is the study run from?
The study was run from Gilead Sciences, Inc. (USA) and took place at 173 centres globally.

When is the study starting and how long is it expected to run for?
February 2020 to June 2020

Who is funding the study?
Gilead Sciences, Inc. (USA)

Who is the main contact?
GileadClinicalTrials@gilead.com

Contact information

Ms Devi Sengupta
Scientific

333 Lakeside Drive
Foster City
California
94404
United States of America

Phone +1 646-351-9642
Email Devi.SenGupta@gilead.com

Study information

Study designPhase 3 randomized open-label multi-center study
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleA phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe COVID-19
Study hypothesisThe odds of improvement for the 5-day treatment group (Treatment Group 1) is different from the odds of improvement for the 10-day treatment group (Treatment Group 2) with respect to clinical status assessed by a 7-point ordinal scale on Day 14
Ethics approval(s)Approved 25/03/2020, North East - Tyne & Wear South Research Ethics Committee (HRA Jarrow, Room 001, Jarrow Business Centre, Rolling Mill Road, Jarrow, NE32 3DT, UK; +44 (0)207 1048084; nrescommittee.northeast-tyneandwearsouth@nhs.net), ref: 20/NE/0104
ConditionCOVID-19 (SARS-CoV-2 infection)
InterventionThe study was conducted in two parts.

In Part A, approximately 400 participants who met all eligibility criteria and who were not mechanically ventilated were randomized via an interactive web response system (IWRS) in a 1:1 ratio into one of the following treatment groups:
Treatment Group 1: continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2, 3, 4, and 5
Treatment Group 2: continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10

After Part A completed enrollment, Part B enrolled up to 5600 additional participants, including some who were on mechanical ventilation. In Part B, participants who met all of the eligibility criteria were enrolled to receive the following (based on whether they were mechanically ventilated at enrollment):
Mechanically Ventilated Treatment Group: continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10
Extension Treatment Group: continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10
If the 5-day dosing regimen used in Treatment Group 1 of Part A is selected for Part B, all participants in the Extension Treatment Group and all new participants will be reassigned to receive treatment for a total of 5 days. National and local regulatory authorities will be informed.

All participants were followed-up for 28 days.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Remdesivir (RDV)
Primary outcome measureThe odds of ratio for improvement on a 7-point ordinal scale on day 14, calculated from daily scores taken each day from baseline to day 14. (The ordinal scale is an assessment of the clinical status at a given day. The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol Remdesivir administration 7. Not hospitalized)
Secondary outcome measuresAdverse Events recorded from patient medical records from the time of consent up to Day 28 (+/-5 days). Serious adverse events were reported up to 30 days of last dose and after the protocol defined follow-up period if deemed relevant to the use of study drug.
Overall study start date11/02/2020
Overall study end date30/06/2020

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participants6,000
Total final enrolment4891
Participant inclusion criteria1. Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under ICH E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants ≥ 18 years of age), or willing and able to provide assent (participants ≥12 and <18 years of age, where locally and nationally approved) prior to performing study procedures. For participants ≥12 and <18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures
2. Aged ≥ 18 years (at all sites), or aged ≥12 and <18 years of age weighing ≥40 kg (where permitted according to local law and approved nationally and by the relevant institutional review board [IRB] or independent ethics committee [IEC])
3. SARS-CoV-2 infection confirmed by PCR test ≤4 days before randomization
4. Currently hospitalized
5. SpO2 ≤94% on room air or requiring supplemental oxygen at screening
6. Radiographic evidence of pulmonary infiltrates
7. Men and women of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
Participant exclusion criteria1. Participation in any other clinical trial of an experimental treatment for COVID-19
2. Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 <24 hours prior to study drug dosing
3. Evidence of multiorgan failure
4. Mechanically ventilated (including V-V ECMO) ≥5 days, or any duration of V-A ECMO
5. ALT or AST >5 ULN
6. Creatinine clearance <50 mL/min using the Cockcroft-Gault formula for participants ≥18 years of age and Schwartz Formula for participants <18 years of age
7. Positive pregnancy test
8. Breastfeeding woman
9. Known hypersensitivity to the study drug, the metabolites, or formulation excipient
Recruitment start date06/03/2020
Recruitment end date29/05/2020

Locations

Countries of recruitment

  • England
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Korea, South
  • Netherlands
  • Scotland
  • Singapore
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • United Kingdom
  • United States of America
  • Uruguay

Study participating centres

Prince of Wales Hospital
Room G05, Ground Floor
30-32 Ngan Shing Street
Sha Tin
Hong Kong
-
Hong Kong
Queen Mary Hospital
102 Pokfulam Road
2-10 Princess Margaret Hospital Road
Kowloon
Hong Kong
-
Hong Kong
Tokyo Metropolitan Bokutoh Hospital
4-23-15 Kotobashi, Sumida-ku
Toyko
130-8575
Japan
Yokohama Municipal Citizen’s Hospital
1-1, Mitsuzawanishimachi, Kanagawa-ku
Yokohama-shi
Kanagawa
221-0855
221-0855
Japan
Seoul Medical Center
156 Sinnae-ro, Jungnang-gu
Seoul, 2053
2053
Korea, South
National Medical Center
245, Euljiro, Jung-gu
Seoul, 4564
4564
Korea, South
National University Hospital
1E Kent Ridge Road
NUHS Tower Block
119228
119228
Singapore
Singapore General Hospital (SGH)
20 College Road
169856
Singapore
National Centre for Infectious Diseases
16 Jalan Tan Tock Seng
308442
Singapore
National Taiwan University Hospital
No.25, Lane 442, Sec.1, Jingguo Road
Hsinchu City
Hsinchu
30059
Taiwan
Kaohsiung Veterans General Hospital
No. 386, Ta Chung 1st. Road
Kaohsiung City
81362
Taiwan
Hôpital Saint Antoine
184 rue du Faubourg Saint Antoine
Paris
75571
France
Hôpital Saint-André
1 Rue Jean Burguet
Service des maladies infectieuses et tropicales
Bordeaux
3075
France
Hôpital Saint Louis
1 Avenue Claude Vellefaux
Paris
75010
France
Hôtel Dieu – Nantes
1 Place Alexis Ricordeau
Service des Maladies Infectieuses et Tropicales
Nantes
Loire-Atlantique
44093
France
CHU Gui De Chauliac
80, avenue Augustin Fliche, Montpellier
34295
France
Universitatsklinikum
Dusseldorf, Moorenstraße 5, Düsseldorf
40225
Germany
Klinikum St. Georg gGmbH
Delitzscher Strasse 141, Leipzig
Sachsen
4129
Germany
Universitätsklinikum Hamburg Eppendorf
Martinistraße 52
I. Medizinische Klinik und Poliklinik,Hamburg
20246
Germany
Universitatsklinikum Schleswig-Holstein
Arnold Heller Straße 3
Klinik für Innere Medizin I
Kiel
24105
Germany
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
Berlin
13353
Germany
Robert Bosch Krankenhaus
Auerbachstrasse 112
Stuttgart
70376
Germany
Klinikum rechts der Isar der Technischen Universität München
Ismaninger Str. 22
II. Medizinische Klinik und Poliklinik der TU München,München
Bayern
81675
Germany
Klinikum Schwabing
Kölner Platz 1, München
Bayern
80804
Germany
Fondazione IRCCS
Policlinico San Matteo di Pavia, Viale Golgi 19
UOC malattie Infettive I
Pavia
27100
Italy
Ospedale San Raffaele S.r.l. – PPDS
Via Olgettina 60, Isituto Scientifico Universitario San Raffaele,Milano
20132
Italy
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
Pazzale Spedali Civili 1,U.O. di Malattie Infettive, Brescia
25123
Italy
Azienda Ospedaliera Di Padova
Via Giustiniani 2
Unità Operativa Malattie Infettive E Tropicali
Padova,Veneto
35128
Italy
Ospedale Guglielmo Da Saliceto
Via Taverna, 49
Piacenza, Emilia-Romagna
29100
Italy
Comprensorio Amedeo Di Savoia Birago Di Vische
Corso Svizzera 164
Torino,Piemonte
10149
Italy
ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco
Via Giovanni Battista Grassi, 74
Dipartimento di Scienze Biomediche e Cliniche L. Sacco,MilanoLombardia
20157
Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Via Francesco Sforza 35
Milano,Lombardia
20122
Italy
Azienda Ospedaliero Universitaria di Parma
Via Gramsci 14
Parma
43100
Italy
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS
Via Portuense 292
Roma
00149
Italy
ASST di Cremona - Azienda Socio Sanitaria
Territoriale di Cremona
Viale Concordia 1
Cremona,Lombardia
26100
Italy
ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa
Giovanni XXIII,Piazza OMS 1,Bergamo
24127
Italy
Academisch Medisch Centrum Amsterdam
Meibergdreef 9
Amsterdam, Noord-Holland
1105 AZ
Netherlands
Erasmus MC
Dr. Molewaterplein 230
Rotterdam
3015GD
Netherlands
Leids Universitair Medisch Centrum
Albinusdreef 2
Leiden
2333 ZA
Netherlands
Hospital Universitario A Coruña
As Xubias, 84
A Coruña
15006
Spain
Hospital Universitario La Paz – PPDS
Paseo de la Castellana 261, Madrid
28046
Spain
Hospital Universitario de Bellvitge
Feixa Llarga s/n
L'Hospitalet de Llobregat
Barcelona
8907
Spain
Hospital Regional Universitario de Malaga – Hospital General
Avda. Carlos Haya, s/n
Servicio de Enfermedades Infecciosas,Malaga
29010
Spain
Hospital Universitari i Politecnic La Fe de Valencia
Avenida Fernado Abril Martorell, 106
Valencia
46026
Spain
Hospital Universitario Virgen del Rocio – PPDS
Avenida Manuel Siurot s/n, Sevilla
41013
Spain
Hospital Universitario Vall d'Hebrón – PPDS
Passeig de la Vall d'Hebron, 119
Barcelona
8035
Spain
Hospital Universitario de Cruces
Cruces Plaza, S/N
Unidad enfermedades infecciosas,Barakaldo
48903
Spain
Hospital Universitario Fundacion Jimenez Diaz
Av. Reyes Católicos 2
Madrid
28040
Spain
Hospital Universitario 12 de Octubre
Avenida de Andalucía s/n
Madrid
28041
Spain
Hospital Clinic de Barcelona
C/ Villarroel 170
Barcelona
08036
Spain
Hospital Universitario Ramon y Cajal
Ctra. de Colmenar, Km. 9,100, Madrid
28034
Spain
Hospital Universitario Principe de Asturias
Carretera de Alcala Meco s/n, Madrid
28805
Spain
Karolinska University Hospital
Hälsovägen
Stockholm
SE-141 86
Sweden
Sahlgrenska Universitetssjukhuset
SE-41685, Göteborg
Vastra Gotalands lan
41685
Sweden
Skånes Universitetssjukhus Malmö
Ruth Lundskogs gata 3, Infektionskliniken
Malmö
SE-20502
Sweden
Ospedale Regionale Lugano Civico
Via Tesserete 46, Lugano
Ticino (it)
6900
Switzerland
Hopitaux Universitaires de Geneve (HUG),
4 Rue Gabrielle Perret-Gentil, Geneve
1205
Switzerland
Universitätsspital Zürich
Rämistrasse 100
Klinik für Infektiologie und Spitalhygiene
Zürich
8091
Switzerland
Manchester Royal Infirmary – PPDS
Oxford Road Campus
Manchester Foundation Trust Oxford Road
Manchester
M13 9WL
United Kingdom
Royal Free London NHS Foundation Trust
17 Lyndhurst Gardens
Hampstead
London
NW3 5NU
United Kingdom
University College London Hospitals (UCLH)
235 Euston Road
London
NW1 2BU
United Kingdom
Derriford Hospital
Derriford Road
Crownhill
Plymouth
PL6 8DH
United Kingdom
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF
United Kingdom
St Mary's Hospital
Praed Street
London
W2 1NY
United Kingdom
Queen Elizabeth University Hospital – PPDS
1345 Govan Road
Glasgow
G51 4TF
United Kingdom
Royal Lancaster Infirmary
-
Lancaster
LA1 4RP
United Kingdom
Castle Hill Hospital
Castle Road
Cottingham
HU16 5JQ
United Kingdom
King's College Hospital NHS Foundation Trust
King's College Hospital
Denmark Hill
London
SE5 9RS
United Kingdom
Royal Liverpool University Hospital
Prescot Street
Liverpool
L7 8XP
United Kingdom
North Manchester General Hospital – PPDS
Delaunays Road
Crumpsall
Manchester
M8 5RB
United Kingdom
Royal Infirmary of Edinburgh – PPDS
51 Little France Crescent
Edinburgh
EH16 4SA
United Kingdom
Northwick Park Hospital
Watford Road
Harrow
London
HA1 3UJ
United Kingdom
Icahn School of Medicine at Mount Sinai
17 East 102nd Street
8th Floor, New York
10029
United States of America
Mount Sinai Beth Israel
350 East 17th Street, 3rd floor, New York
1003
United States of America
Mount Sinai West
1000 10th Avenue, Suite 2T, New York, NY
10019
United States of America
Mount Sinai Morningside
440 West 114th Street, 6th floor, New York, NY
10025
United States of America
St Joseph Hospital – Eureka
2700 Dolbeer Street,Eureka
California
95501
United States of America
Kadlec Regional Medical Center
888 Swift Boulevard, Richland
Washington
99352
United States of America
Jamaica Hospital Medical Center
800 Van Wyck Expressway,Jamaica
New York
11418
United States of America
Mission Hospital
27700 Medical Center Road, Mission Viejo
California
92691
United States of America
Hennepin Healthcare Research Institute
701 Park Avenue
Minneapolis, Minnesota
55415
United States of America
Hackensack University Medical Center
30 Prospect Avenue
Hackensack
New Jersey
7601
United States of America
Henry Ford Hospital
2799 West Grand Blvd
Detroit, Michigan
48202
United States of America
James J Peters Veterans Administration Medical Center – NAVREF
130 West Kingsbridge Road, Bronx, New York
10468
United States of America
St.Joseph Hospital – Orange
1100 West Stewart Drive
Orange,California
92868
United States of America
University of Colorado
4200 East 9th Avenue
Denver, Colorado
80262
United States of America
Providence Saint Patrick Hospital
500 West Broadway, Missoula
Montana
59802
United States of America
Inland Northwest Research
910 West 5th Avenue
Suite500,Spokane,Washington
99204
United States of America
Temple University Hospital
3401 North Broad Street ,Philadelphia
Pennsylvania
19140
United States of America
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA
19104
United States of America
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, Pennsylvania
19104
United States of America
Providence Regional Medical Center Everett
1321, Colby Avenue
Office B3-018
Everett, Washington
98122
United States of America
Long Island Jewish Medical Center
270-05 76th Aven
New Hyde Park, NY
11040
United States of America
Northwell Health,
300 Community Drive
Manhasset, New York
11030
United States of America
Mills Peninsula Medical Center
1501 Trousdale Drive, Burlingame
California
94010
United States of America
Tulane University School of Medicine
1415 Tulane Avenue
New Orleans
Louisiana
70112
United States of America
Swedish Medical Center
747 Broadway
Seattle, Washington
98122
United States of America
Baylor University Medical Center
3500 Gaston Ave
Dallas, Texas
75246
United States of America
Baylor Scott & White All Saints Medical Center
1400 8th Ave
Fort Worth, TX
76104
United States of America
Baylor Scott & White Medical Center -Temple
2401 S 31st St
Temple, TX
76508
United States of America
Sutter Santa Rosa Regional Hospital
30 Mark West Springs Rd
Santa Rosa, California
95403
United States of America
Houston Methodist Hospital
6565 Fannin Street, TX Medical Flagship, Houston
Texas
77030
United States of America
Indiana University School of Medicine-Indianapolis
545 Barnhill Drive
Emerson Hall
Suite 421, Indianapolis
Indiana
46077
United States of America
Rose Medical Center
4567 East 9th Avenue
Denver, Colorado
80220
United States of America
Providence St. John’s Health Center
2121 Santa Monica Blvd
1st Floor, Santa Monica
California
90404
United States of America
Prisma Health–Midlands
5 Richland Medical Park Drive, Columbia
South Carolina
29203
United States of America
Prisma Health-Greenville Memorial Hospital
701 Grove Rd
Greenville, SC
29605
United States of America
University Hospitals Cleveland Medical Center
11100 Euclid Ave
Cleveland, Ohio
44106
United States of America
John H. Stroger, Jr. Hospital of Cook County
1901 West Harrison Street, Chicago
Illinois
60612
United States of America
University of Utah – PPDS
50 N Medical Drive
Salt Lake City, Utah
84132
United States of America
University Of Iowa Hospitals And Clinics
200 Hawkins Drive
Iowa City, Iowa
52242
United States of America
UT Southwestern Medical Center–ID Clinical Research
1936 Amelia Court
2nd Floor
Dallas, TX
75235
United States of America
UT Southwestern Medical Center–ID Clinical Reseach
1936 Amelia Court
2nd Floor
Dallas, TX
75235
United States of America
Holy Cross Hospital
1500 Forest Glen Road
Silver Spring, Maryland
20910
United States of America
Franciscan Health System Research Center
1708 South Yakima Avenue, Suite 300
Tacoma, Washington
98405
United States of America
University of Michigan
1500 East Medical Center Drive, Ann Arbor
Michigan
48109
United States of America
Inova Fairfax Hospital
3300 Gallows Road
Falls Church, Virginia
22042
United States of America
Sutter Medical Center Sacramento
2825 Capitol Avenue
Sacramento, California
95816
United States of America
Sutter Roseville Medical Center
One Medical Plaza
Roseville, CA
95661
United States of America
Jacobi Medical Center
1400 Pelham Parkway South, Bronx, New York
10461
United States of America
California Pacific Medical Center
1101 Van Ness Avenue, San Francisco
California
94109
United States of America
Virginia Mason Medical Center
1100 9th Avenue
Seattle, Washington
98101
United States of America
Tacoma General Hospital
315 Martin Luther King Jr Way ,Tacoma, Washington
98405
United States of America
Liver Institute at Methodist Dallas
1411 North Beckley Avenue, Pavillion III
Suite 268, Dallas
Texas
75203
United States of America
New York Presbyterian Hospital - Weill-Cornell
525 East 68th Street
New York
10065
United States of America
Brigham and Womens Hospital
75 Francis Street, Division of Infectious Disease
Brigham and Women's Hospital, Boston, Massachusetts
2115
United States of America
Alta Bates Summit Medical Center
2450 Ashby Avenue
Berkeley, California
94705
United States of America
Virginia Hospital Center
1701 North George Mason Drive
Arlington, Virginia
22205
United States of America
Kaiser Permanente
Skyline Medical Office
1375 East 20th Avenue
Denver, CO
80204
United States of America
Kaiser Permanente Center For Health Research
3800 North Interstate Avenue, Portland
Oregon
97227
United States of America
Kiaser Westside Medical Center
2875 NW Stucki Ave., Hillsboro, OR
97124
United States of America
University of Chicago
5841 S. Maryland Ave.
Chicago, Illinois
60637
United States of America
Somerset Medical Center
110 Rehill Avenue
Somerville, New Jersey
8876
United States of America
Robert Wood Johnson University Hospital New Brunswick
1 RWJ Place
New Brunswick, NJ
08901
United States of America
Newark Beth Isreael Medical Center
201 Lyons Avenue
Newark, NJ
07112
United States of America
Danbury Hospital
24 Hospital Avenue
Danbury, Connecticut
6810
Uruguay
Columbia University Medical Center
622 W 168th St
PH E101, New York
10032
United States of America
Yale-New Haven Hospital
20 York St, New Haven
Connecticut
06510-3220
United States of America
Tufts Medical Center – PPDS
800 Washington Street, Boston
Massachusetts
2111
United States of America
Providence Saint Vincent's Medical Center
9205 Southwest Barnes Road, Portland
Oregon
97225
United States of America
St Joseph's Regional Medical Center
703 Main Street
Paterson, New Jersey
7503
United States of America
Mayo Clinic – PPDS
200 First Street Southwest, Rochester
Minnesota
55905
United States of America
Hoag Memorial Hospital Presbyterian
One Hoag Drive, Newport Beach
California
92663
United States of America
Virginia Commonwealth University
1250 East Marshall Street
Richmond, Virginia
23298
United States of America
Maine Medical Center
22 Bramhall Street
Portland, Maine
4102
United States of America
Eden Medical Center
20103 Lake Chabot Road
Castro Valley
California
94546
United States of America
Rush University Medical Center
1653 W. Congress Parkway, Chicago
Illinois
60612
United States of America
Kaiser Permanente Oakland Medical Center
3600 Broadway
Oakland, California
94611
United States of America
Kaiser Permanente San Francisco Medical Center
2425 Geary Blvd. San Francisco, CA
94115
United States of America
Kaiser Permanente South San Francisco Medical Center
1200 El Camino Real, San Francisco, CA
94080
United States of America
Kaiser Permanente San Jose Medical Center
250 Hospital Parkway, San Jose, CA
95119
United States of America
Kaiser Permanente San Leandro Medical Center
2500 Merced Street San Leandro, CA
94577
United States of America
Kaiser Permanente Santa Clara
700 Lawrence Expressway, Santa Clara, CA
95051
United States of America
Providence St Peter Hospital
, 413 Lilly Road Northeast, Olympia
Washington
98506
United States of America
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, Massachusetts
2215
United States of America
Stanford University School of Medicine
300 Pasteur Drive
Stanford, California
94305
United States of America
Miriam Hospital
164 Summitt Avenue
Providence
Rhode Island
2906
United States of America
Woodland Hills Medical Center
5601 De Soto Avenue, Woodland Hills, CA
91365
United States of America
Ontario Medical Center
2295 S. Vineyard Avenue
Ontario, CA
91761
United States of America
San Diego Medical Center
9455 Clairemont Mesa Blvd
San Diego, CA
92123
United States of America
Zion Medical Center
4647 Zion Avenue, San Diego, CA
92120
United States of America
Downey Medical Center
9333 Imperial Highway
Downey, CA
90241
United States of America
Riverside Medical Center
10800 Magnolia Avenue
Riverside, CA
92505
United States of America
Kaiser Permanente Los Angeles Medical Center
4867 West Sunset Boulevard, Los Angeles, California
90027
United States of America
Orange County Anaheim Medical Center
3440 E. La. Palma Avenue
Anaheim, CA
92806
United States of America
West Los Angeles Medical Center
6041 Cadillac Avenue, Los Angeles, CA
90034
United States of America
Moreno Valley Medical Center
27300 Iris Avenue
Moreno Valley, CA
92555
United States of America
Fontana Medical Center
9961 Sierra Avenue
Fontana, CA
92335
United States of America
Panorama City Medical Center
13651 Willard Street
Panorama City, CA
91402
United States of America
South Bay Medical Center
25825 S. Vermont Avenue
Harbor City, CA
90710
United States of America
Duke University Medical Center
2301 Erwin Road
Durham, North Carolina
27710
United States of America
Dartmouth-Hitchcock Medical Center
1 Medical Center Drive
Lebanon, New Hampshire
3766
United States of America

Sponsor information

Gilead Sciences (United States)
Industry

333 Lakeside Drive
Foster City
California
94404
United States of America

Phone +1-833-445-3230
Email GileadClinicalTrials@gilead.com
Website http://www.gilead.com/
ROR logo "ROR" https://ror.org/056546b03

Funders

Funder type

Industry

Gilead Sciences
Government organisation / For-profit companies (industry)
Alternative name(s)
Gilead, Gilead Sciences, Inc.
Location
United States of America

Results and Publications

Intention to publish date01/06/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.

The Protocol is available at the following address within the supplemental materials:
https://www.nejm.org/doi/full/10.1056/NEJMoa2015301

A redacted version of the latest protocol and statistical analysis plan, will be available on ClinicalTrials.gov when results are submitted: https://clinicaltrials.gov/ct2/show/NCT04292899
IPD sharing planThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting non conflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science’s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com . Data will become available 18 months after study completion and will be accessible in a secured external environment. More information on Gilead’s data sharing policy can be found here: https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results No No
Results article results 27/05/2020 29/10/2020 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

19/03/2021: Added EudraCT and clinicaltrials.gov links to basic results (scientific).
02/11/2020: Trial’s existence confirmed by North East - Tyne & Wear South Research Ethics Committee.